You are here

How do leukaemia cells harness their epigenome to become resistant to targeted therapies?

Description 
The acquisition of resistance to therapies by cancer cells, sadly, is often inevitable. To effectively treat cancer, we need to understand how individual tumour cells are capable of escaping treatments through a process known as cellular plasticity. This adaptive process is driven by distinct cellular pathways and chromatin states that are yet to be clearly identified. This project will aim to elucidate how the chromatin landscape contributes to the plasticity and stability of individual tumour cells.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
Chromatin, plasticity, adaptive tumour cells
School 
School of Translational Medicine » Australian Centre for Blood Diseases (ACBD)
Available options 
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Joint PhD/Exchange Program
Time commitment 
Full-time
Top-up scholarship funding available 
Yes
Year 1: 
$5000
Physical location 
Australian Centre for Blood Diseases

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.